| 81.05 2.32 (2.95%) | 06-12 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 94.75  |
1-year : | 110.67 |
| Resists | First : | 81.12 |
Second : | 94.75 |
| Pivot price | 72.87 |
|||
| Supports | First : | 70 |
Second : | 63.13 |
| MAs | MA(5) : | 77.84 |
MA(20) : | 71.35 |
| MA(100) : | 74.54 |
MA(250) : | 101.62  |
|
| MACD | MACD : | 3 |
Signal : | 1.9 |
| %K %D | K(14,3) : | 93.1 |
D(3) : | 91.5 |
| RSI | RSI(14): 72.2 |
|||
| 52-week | High : | 148.14 | Low : | 57 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ NVO ] has closed above the upper band by 0.3%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 24.4% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 81.22 - 81.54 | 81.54 - 81.82 |
| Low: | 79.02 - 79.42 | 79.42 - 79.77 |
| Close: | 80.36 - 81.01 | 81.01 - 81.57 |
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Thu, 12 Jun 2025
Why Novo Nordisk Stock Pumped Higher on Thursday - Yahoo Finance
Thu, 12 Jun 2025
Why Novo Nordisk (NVO) Outpaced the Stock Market Today - Yahoo Finance
Thu, 12 Jun 2025
Novo to begin late-stage trial to test new obesity drug (NVO) - Seeking Alpha
Wed, 11 Jun 2025
Double Dose of AI Drug Deals Fails to Give Novo Nordisk Stock (NVO) a Boost - TipRanks
Tue, 10 Jun 2025
Novo Nordisk Stock (NVO) Rallies amid New Phase 3 Study for CagriSema - TipRanks
Tue, 10 Jun 2025
Why Novo Nordisk Stock Just Popped - The Motley Fool
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - General
|
|
| Shares Out | 3,370 (M) |
| Shares Float | 3,180 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 9.8 (%) |
| Shares Short | 27,580 (K) |
| Shares Short P.Month | 19,070 (K) |
| EPS | 3.59 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 31.2 |
| Profit Margin | 34.5 % |
| Operating Margin | 49.6 % |
| Return on Assets (ttm) | 23.2 % |
| Return on Equity (ttm) | 88.1 % |
| Qtrly Rev. Growth | 19.5 % |
| Gross Profit (p.s.) | 76.14 |
| Sales Per Share | 89.95 |
| EBITDA (p.s.) | 46.07 |
| Qtrly Earnings Growth | 15 % |
| Operating Cash Flow | 131,240 (M) |
| Levered Free Cash Flow | 77,730 (M) |
| PE Ratio | 22.51 |
| PEG Ratio | 0 |
| Price to Book value | 2.59 |
| Price to Sales | 0.9 |
| Price to Cash Flow | 2.08 |
| Dividend | 1.1 |
| Forward Dividend | 0 |
| Dividend Yield | 1.3% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|